• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

High dose urokinase for restoration of patency of occluded permanent central venous catheters in hemodialysis patients.

作者信息

Shavit L, Lifschitz M, Plaksin J, Grenader T, Slotki I

机构信息

Nephrology Unit Shaare Zedek Medical Center, Jerusalem, Israel.

出版信息

Clin Nephrol. 2010 Oct;74(4):297-302. doi: 10.5414/cnp74297.

DOI:10.5414/cnp74297
PMID:20875382
Abstract

BACKGROUND

Catheter thrombosis is common and results in inadequate dialysis treatment and, frequently, in catheter loss. Since dialysis treatment runs on a strict schedule, occluded catheters need to be restored in a timely and cost effective manner. We present a new shortened protocol of urokinase infusion that allows hemodialysis to be performed within 90 minutes.

METHODS

To chronic hemodialysis patients, who developed complete catheter occlusion, urokinase was infused simultaneously through both lumens of the catheter (125,000 units to each lumen) over 90 minutes. Technical success was defined as restoring blood pump speed to at least 250 ml/min. We determined the average time from catheter placement to first clot event (primary patency PP), recurrent clot event after urokinase treatment (secondary patency SP), catheter salvage rate and cause for removal.

RESULTS

37 catheters developed total thrombosis and urokinase was used to restore patency one or more times (total 47 treatments). Catheter salvage rate was 97 %. The average time of PP was 152 ± 56 days (7 - 784 days). Nine patients (30%) developed recurrent occlusion and the average time of SP was 64 ± 34 days (2 - 364 days). One catheter was removed because of dysfunction due to thrombosis. Other catheters were removed due to infection, fistula maturation or fell out spontaneously. Hemodialysis was performed immediately after treatment with blood speed of 250 ml/min in all patients.

CONCLUSION

Our protocol is highly effective, short, and allows to restore patency of totally occluded central venous catheters with minimal disruption of the dialysis session.

摘要

相似文献

1
High dose urokinase for restoration of patency of occluded permanent central venous catheters in hemodialysis patients.
Clin Nephrol. 2010 Oct;74(4):297-302. doi: 10.5414/cnp74297.
2
High-dose intradialytic urokinase to restore the patency of permanent central vein hemodialysis catheters.大剂量透析中尿激酶用于恢复永久性中心静脉血液透析导管的通畅性。
Am J Kidney Dis. 1998 May;31(5):841-7. doi: 10.1016/s0272-6386(98)70054-x.
3
Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.重组尿激酶用于恢复阻塞的中心静脉通路装置的通畅性:一项双盲、安慰剂对照试验。
Thromb Haemost. 2004 Sep;92(3):575-82. doi: 10.1160/TH03-11-0686.
4
Efficacy of urokinase lock to treat thrombotic dysfunction of tunneled hemodialysis catheters: A retrospective cohort study.尿激酶封管治疗带隧道血液透析导管血栓形成功能障碍的疗效:一项回顾性队列研究。
J Vasc Access. 2019 Jan;20(1):60-69. doi: 10.1177/1129729818779549. Epub 2018 Jun 12.
5
Alteplase versus urokinase for occluded hemodialysis catheters.阿替普酶与尿激酶用于治疗闭塞性血液透析导管
Ann Pharmacother. 2003 Jan;37(1):27-33. doi: 10.1345/aph.1C105.
6
Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial.重组尿激酶在恢复阻塞的中心静脉通路装置通畅方面安全有效:一项多中心国际试验。
Crit Care Med. 2004 Oct;32(10):1990-6. doi: 10.1097/01.ccm.0000142706.01717.eb.
7
Urokinase efficacy in the restoration of hemodialysis catheter function.
J CANNT. 1998 Spring;8(2):17-9.
8
Prospective Audit to Study urokinaSe use to restore Patency in Occluded centRal venous caTheters (PASSPORT 1).前瞻性审计研究尿激酶用于恢复中心静脉导管堵塞通畅性(PASSPORT 1)。
J Vasc Access. 2019 Nov;20(6):752-759. doi: 10.1177/1129729819869095. Epub 2019 Aug 30.
9
Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.阿替普酶与尿激酶用于闭塞性血液透析导管:一项随机试验。
Hemodial Int. 2016 Jul;20(3):378-84. doi: 10.1111/hdi.12391. Epub 2016 Feb 7.
10
Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.糖尿病会降低首效尿激酶溶栓治疗后行血液透析患者隧道式导管的通畅率。
Ren Fail. 2018 Nov;40(1):384-389. doi: 10.1080/0886022X.2018.1487856.

引用本文的文献

1
Diabetes decreases patency of tunneled catheters in hemodialysis patients after first effective thrombolysis with urokinase.糖尿病会降低首效尿激酶溶栓治疗后行血液透析患者隧道式导管的通畅率。
Ren Fail. 2018 Nov;40(1):384-389. doi: 10.1080/0886022X.2018.1487856.